Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph Drabick, Montaser F. Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L. Tennant, Christopher M. Smith, Eugene P. Kennedy, Charles J. Link, Nicholas N. Vahanian, Jiayi Yu, Steven S. Shen, Erik L. Brincks, Gabriela R. Rossi, David Munn, Mohammed Milhem

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences